Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Fahadullah Khan, Mohammad Ismail, Qasim Khan & Zahid Ali. (2018) Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review. Expert Opinion on Drug Safety 17:10, pages 1029-1039.
Read now
Read now
Brian Wispelwey & Katherine R Schafer. (2010) Fluoroquinolones in the management of community-acquired pneumonia in primary care. Expert Review of Anti-infective Therapy 8:11, pages 1259-1271.
Read now
Read now
K. Bober. (2008) Determination of Selected Quinolones and Fluoroquinolones by Use of TLC. Analytical Letters 41:10, pages 1909-1913.
Read now
Read now
Articles from other publishers (35)
Muhammad Jamshaid, Muhammad Imran Khan, Javier Fernandez, Abdallah Shanableh, Tajamal Hussain & Aziz ur Rehman. (2022)
Synthesis of Ti
4+
doped Ca-BiFO
3
for the enhanced photodegradation of moxifloxacin
. New Journal of Chemistry 46:41, pages 19848-19856.
Crossref
Crossref
Mohamed Kadry Taher, James A G Crispo, Yannick Fortin, Ryan Moog, Douglas McNair, Lise M Bjerre, Franco Momoli, Donald Mattison & Daniel Krewski. (2021) Systemic quinolones and risk of acute liver failure III: A nested case–control study using a US electronic health records database. Journal of Gastroenterology and Hepatology 36:8, pages 2307-2314.
Crossref
Crossref
P.C. Sharma, R. Goyal, A. Sharma, D. Sharma, N. Saini, H. Rajak, S. Sharma & V.K. Thakur. (2020) Insights on fluoroquinolones in cancer therapy: chemistry and recent developments. Materials Today Chemistry 17, pages 100296.
Crossref
Crossref
S. Lakshmi Prabavathi, K. Saravanakumar, T. T. I. Nkambule, V. Muthuraj & G. Mamba. (2020) Enhanced photoactivity of cerium tungstate-modified graphitic carbon nitride heterojunction photocatalyst for the photodegradation of moxifloxacin. Journal of Materials Science: Materials in Electronics 31:14, pages 11434-11447.
Crossref
Crossref
Moumita Hazra. (2019) A RATIONAL PHARMACOTHERAPEUTIC STUDY IN PHARMACOVIGILANCE: A COMPARATIVE ASSESSMENT OF SAFETY BETWEEN TOPICAL 1% NADIFLOXACIN AND 0.1% ADAPALENE COMBINATION THERAPY AND TOPICAL 1% NADIFLOXACIN AND 0.025% TRETINOIN COMBINATION THERAPY, IN MILD TO MODERATE ACNE, IN TERTIARY CARE HOSPITALS, IN INDIA. Journal of Evidence Based Medicine and Healthcare 6:35, pages 2366-2371.
Crossref
Crossref
G. Röhrig, I. Becker, K. Pappas, M. C. Polidori & R. J. Schulz. (2017) Analysis of cytopenia in geriatric inpatientsAnalyse von Zytopenien bei stationär geriatrischen Patienten. Zeitschrift für Gerontologie und Geriatrie 51:2, pages 231-236.
Crossref
Crossref
Christine E. Kistler, Sheryl Zimmerman, Kezia Scales, Kimberly Ward, David Weber, David Reed, Mallory McClester & Philip D. Sloane. (2017) The Antibiotic Prescribing Pathway for Presumed Urinary Tract Infections in Nursing Home Residents. Journal of the American Geriatrics Society 65:8, pages 1719-1725.
Crossref
Crossref
Somaye Cheraghi, Mohammad A. Taher, Hassan Karimi-Maleh & Ehsan Faghih-Mirzaei. (2017) A nanostructure label-free DNA biosensor for ciprofloxacin analysis as a chemotherapeutic agent: an experimental and theoretical investigation. New Journal of Chemistry 41:12, pages 4985-4989.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
368
381
.
Carlos Martín Ardila, Juan Felipe Martelo-Cadavid, Gina Boderth-Acosta, Astrid Adriana Ariza-Garcés & Isabel C. Guzmán. (2015) Adjunctive moxifloxacin in the treatment of generalized aggressive periodontitis patients: clinical and microbiological results of a randomized, triple-blind and placebo-controlled clinical trial. Journal of Clinical Periodontology 42:2, pages 160-168.
Crossref
Crossref
Edison Andrés Cruz Olivo, Jorge Hernán Ramirez Escobar & Adolfo Contreras Rengifo. (2014) La moxifloxacina como coadyuvante en el tratamiento de las periodontitis. Revista Clínica de Periodoncia, Implantología y Rehabilitación Oral 7:3, pages 200-208.
Crossref
Crossref
Varsha Narayanan, Salman Motlekar, Ganesh Kadhe & Seema Bhagat. (2014) Efficacy and Safety of Nadifloxacin for Bacterial Skin Infections: Results from Clinical and Post-Marketing Studies. Dermatology and Therapy 4:2, pages 233-248.
Crossref
Crossref
Thamir M. Alshammari, E. Paul Larrat, Haley J. Morrill, Aisling R. Caffrey, Brian J. Quilliam & Kerry L. Laplante. (2014) Risk of hepatotoxicity associated with fluoroquinolones: A national case–control safety study. American Journal of Health-System Pharmacy 71:1, pages 37-43.
Crossref
Crossref
Matthias Troeltzsch, Christoph Pache, Florian Andreas Probst, Markus Troeltzsch, Michael Ehrenfeld & Sven Otto. (2014) Antibiotic Concentrations in Saliva: A Systematic Review of the Literature, With Clinical Implications for the Treatment of Sialadenitis. Journal of Oral and Maxillofacial Surgery 72:1, pages 67-75.
Crossref
Crossref
Shyang Chang. (2013) The meridian system and mechanism of acupuncture: A comparative review. Part 3: Mechanisms of acupuncture therapies. Taiwanese Journal of Obstetrics and Gynecology 52:2, pages 171-184.
Crossref
Crossref
Barton L. Wise, Christine Peloquin, Hyon Choi, Nancy E. Lane & Yuqing Zhang. (2012) Impact of Age, Sex, Obesity, and Steroid Use on Quinolone-associated Tendon Disorders. The American Journal of Medicine 125:12, pages 1228.e23-1228.e28.
Crossref
Crossref
Megan Strauchman & Mark Morningstar. (2012) Fluoroquinolone Toxicity Symptoms in a Patient Presenting with Low Back Pain. Clinics and Practice 2:4, pages e87.
Crossref
Crossref
Paul M. Tulkens, Pierre Arvis & Frank Kruesmann. (2012) Moxifloxacin Safety. Drugs in R&D 12:2, pages 71-100.
Crossref
Crossref
Christoph Justinger, Martin K. Schilling, Martin G. Kees, Anne Kauffels, Katrin Hirschmann, Berit Kopp, Frieder Kees & Otto Kollmar. (2012) Penetration of moxifloxacin into liver tissue. International Journal of Antimicrobial Agents 39:6, pages 505-509.
Crossref
Crossref
Anna Licata, Claudia Randazzo, Ilaria Morreale, Giuseppe Butera, Natale D’Alessandro & Antonio Craxì. (2012) Fluoroquinolone-induced liver injury: three new cases and a review of the literature. European Journal of Clinical Pharmacology 68:5, pages 525-532.
Crossref
Crossref
Eva C. GuinanChristine M. BarbonLeslie A. KalishKalindi ParmarJeff KutokChristy J. MancusoLiat Stoler-BarakEugénie E. SuterJanice D. RussellChristine D. PalmerLeighanne C. GallingtonAnnie VoskertchianJo-Anne VergilioGeoffrey ColeKaya ZhuAlan D’AndreaRobert SoifferJerrold P. WeissOfer Levy. (2011)
Bactericidal/Permeability-Increasing Protein (rBPI
21
) and Fluoroquinolone Mitigate Radiation-Induced Bone Marrow Aplasia and Death
. Science Translational Medicine 3:110.
Crossref
Crossref
J Carl Craft. 2011. Neglected Diseases and Drug Discovery. Neglected Diseases and Drug Discovery
366
411
.
R. J. Andrade & P. M. Tulkens. (2011) Hepatic safety of antibiotics used in primary care. Journal of Antimicrobial Chemotherapy 66:7, pages 1431-1446.
Crossref
Crossref
Eric S. Orman, Hari S. Conjeevaram, Raj Vuppalanchi, James W. Freston, James Rochon, David E. Kleiner & Paul H. Hayashi. (2011) Clinical and Histopathologic Features of Fluoroquinolone-Induced Liver Injury. Clinical Gastroenterology and Hepatology 9:6, pages 517-523.e3.
Crossref
Crossref
Douglas N. Fish. 2011. Textbook of Critical Care. Textbook of Critical Care
943
948
.
Jay W. Mason, Jeffry A. FlorianJrJr, Christine E. Garnett, Thomas E. Moon, Daniel S. Selness & Randol R. Spaulding. (2013) Pharmacokinetics and Pharmacodynamics of Three Moxifloxacin Dosage Forms: Implications for Blinding in Active‐Controlled Cardiac Repolarization Studies. The Journal of Clinical Pharmacology 50:11, pages 1249-1259.
Crossref
Crossref
Matthew E. Falagas, Evridiki K. Vouloumanou, Konstantinos Sgouros, Stavros Athanasiou, George Peppas & Ilias I. Siempos. (2010) Patients included in randomised controlled trials do not represent those seen in clinical practice: focus on antimicrobial agents. International Journal of Antimicrobial Agents 36:1, pages 1-13.
Crossref
Crossref
Xiaohong Shi, Yan Zheng, Wanshan Ma & Yunshan Wang. (2010) Possible involvement of DEC1 on the adverse effects of quinolone antibiotics. Toxicology 271:1-2, pages 1-4.
Crossref
Crossref
Ralf Stahlmann & Hartmut Lode. (2010) Safety Considerations of Fluoroquinolones in the Elderly. Drugs & Aging 27:3, pages 193-209.
Crossref
Crossref
Carlos M. Ardila, Natalia Fernández & Isabel C. Guzmán. (2010) Antimicrobial Susceptibility of Moxifloxacin Against Gram-Negative Enteric Rods From Colombian Patients With Chronic Periodontitis. Journal of Periodontology 81:2, pages 292-299.
Crossref
Crossref
T. E. Albertson, N. C. Dean, A. A. El Solh, M. H. Gotfried, C. Kaplan & M. S. Niederman. (2010) Fluoroquinolones in the management of community-acquired pneumonia. International Journal of Clinical Practice 64:3, pages 378-388.
Crossref
Crossref
Natascia Corti, Alexander Imhof & Christa Wenger. 2010. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions
461
489
.
Cees van Nieuwkoop, Jan W van't Wout, Willem JJ Assendelft, Henk W Elzevier, Eliane MS Leyten, Ted Koster, G Hanke Wattel-Louis, Nathalie M Delfos, Hans C Ablij, Ed J Kuijper, Jan Pander, Jeanet W Blom, Ida C Spelt & Jaap T van Dissel. (2009) Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days). BMC Infectious Diseases 9:1.
Crossref
Crossref
Françoise Van Bambeke & Paul M. Tulkens. (2009) Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin. Drug Safety 32:5, pages 359-378.
Crossref
Crossref
. (2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 17:5.
Crossref
Crossref